Search results
Results from the WOW.Com Content Network
Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock still looks attractive at current levels.
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.
Allurion CEO Shantanu Gaur told Yahoo Finance ... the lack of US approval and the ongoing demand for GLP-1s has pressured the company's stock — which is down 96% to less than $0.50 per share ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
Eli Lilly reported significantly better-than-expected earnings Thursday, with revenue coming in 13% higher than Wall Street estimates of $11.3 billion for the second quarter.That's a 36% jump in ...
Amgen is among several big pharmaceutical players looking for a way into the newly profitable GLP-1 obesity drug market.Chief financial officer Peter Griffith told Yahoo Finance the company is ...
Moody's released a new report Tuesday that reins in Wall Street expectations for the impact of GLP-1s ... impacting stock prices. Read the latest financial and business news from Yahoo Finance.
Main Menu. News. News